pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Fierce Biotech·Sep 14·1 min read
save

Novo rebrands, drops 'Nordisk' to become simply 'Novo' in market push

Sep 14, 2026·read at Fierce Biotech ↗Positive

Novo Nordisk announced a major rebranding that will see the company drop the "Nordisk" part of its everyday brand. The legal name Novo Nordisk A/S remains unchanged, but the company will be known simply as "Novo" in all public communications.

The new visual identity features a right‑facing Apis bull logo and a refreshed logo and tagline "Lasting Health Starts Now," which the company says is intended to be more memorable and relevant to how people engage with their health today.

Alongside the visual changes, Novo introduced a cultural framework called "The Novo Way," outlining principles to drive innovation and faster, consumer‑driven market response as it competes with rivals such as Eli Lilly.

source

This writeup was produced by pharmadog from original reporting by Fierce Biotech.

Original headline: “No more Nordisk as Novo goes it alone amid rebranding push”

read at Fierce Biotech ↗
555 words · retrieved Sep 14
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
NOVO28LILLY9Novo Nordisk Inc9ELI LILLY CO6Sanofi3GLAXOSMITHKLINEJOHNSON & JOHNSONPFIZER
drugs
Ozempic15Wegovy15Wegovy Pill8Rybelsus5MOUNJARO4Obesity4ZEPBOUND4tirzepatide4semaglutide3FOUNDAYO2orforglipron calcium2
topics
Obesity4Type 2 Diabetes4Big Pharma

related stories

  • Aug 27Myriad catalysts on deck for obesity’s brightest stars as market continues to accelerateBioSpace
  • Sep 30Lilly builds commercial case for GLP-1 products over Novo with indirect analysesBioSpace
  • Sep 21Novo’s plan to hit $23B in revenue by 2035 leaves investors wantingBioSpace
  • Aug 19Novo takes first round of oral obesity duel. Can it stay ahead of Lilly?BioSpace
  • Aug 5Novo CEO accepts ‘couple of setbacks’ in R&D as CagriSema posts more mixed dataFierce Biotech